How rare is pancreatitis on Saxenda?

About 0.2 to 0.3 percent of liraglutide users in trials versus under 0.1 percent on placebo. Roughly 1 case per 300 to 500 patient-years of treatment.

What does Saxenda pancreatitis pain feel like?

Severe, steady, deep pain in the upper middle abdomen that often radiates to the back. It is paired with persistent vomiting and sometimes fever. It is not the same as normal early-treatment nausea.

Should I stop Saxenda if my stomach hurts?

Mild GI symptoms during titration are normal. Stop and seek care for severe persistent abdominal pain, pain radiating to the back, or pain with vomiting and fever.

Can I restart Saxenda after a pancreatitis episode?

No. The FDA label says Saxenda should not be restarted if pancreatitis is confirmed. Most prescribers also avoid switching to other GLP-1 agonists since the class carries the same warning.

Does Saxenda cause gallstones?

Yes, at a higher rate than placebo. The SCALE Obesity trial showed roughly 2.5 percent on Saxenda versus 1.0 percent on placebo. Rapid weight loss is the main driver.

Does Saxenda cause hypoglycemia?

Not by itself in non-diabetic patients. The risk rises when combined with insulin or a sulfonylurea in patients with type 2 diabetes, in which case dose adjustments of those drugs are usually needed.

Is the thyroid cancer warning on Saxenda related to pancreatitis?

No. The medullary thyroid carcinoma warning comes from rodent studies and is a separate concern. It contraindicates Saxenda in people with personal or family history of MTC or MEN 2 syndrome.

Can Saxenda cause IBS, colitis, or other gut conditions?

Saxenda commonly causes nausea, diarrhea, or constipation during titration. It is not a recognized cause of inflammatory bowel disease or true IBS. New persistent gut symptoms after treatment should be evaluated on their own merits.

Does Saxenda cause hair loss, hot flashes, or acne?

Hair loss is uncommonly reported with rapid weight loss generally rather than as a direct drug effect. Hot flashes, acne, and erectile dysfunction are not established Saxenda side effects in the FDA label.

Are blood clots, seizures, or hives Saxenda side effects?

Blood clots and seizures are not labeled adverse effects. Hives and itchy skin appear in rare-frequency lists and can indicate an allergic reaction. Severe allergic symptoms require stopping the drug immediately.

Can Saxenda cause UTIs or yeast infections?

Saxenda is not associated with increased UTI or yeast infection rates. That signal exists for SGLT2 inhibitors, a different drug class for diabetes.

Does Saxenda cause cancer?

The only labeled cancer concern is medullary thyroid carcinoma, based on rodent data. Liraglutide is contraindicated in patients with personal or family history of MTC or MEN 2. There is no established link to other cancers in humans.

Can Saxenda Cause Pancreatitis?

Summary: Saxenda carries an FDA-labeled warning for acute pancreatitis as a class effect of GLP-1 receptor agonists. The absolute risk is low, roughly 0.2 to 0.3 percent in trials, but severe abdominal pain radiating to the back means stop the drug and get evaluated.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Yes. Saxenda (liraglutide 3.0 mg) can cause acute pancreatitis. The FDA-approved prescribing information lists pancreatitis as a serious warning, and the drug should be discontinued promptly if pancreatitis is suspected ^[1]. The absolute risk is small, but it is real, and the symptoms are unmistakable once you know what to look for.

Here is the FDA position, the trial numbers, the symptoms, the risk factors, and the rules for stopping the drug.

What the FDA label actually says

The Saxenda prescribing information includes a boxed-adjacent Warnings and Precautions section on acute pancreatitis. The exact wording is that pancreatitis, "including fatal and non-fatal hemorrhagic or necrotizing pancreatitis," has been reported in patients treated with liraglutide in postmarketing data ^[1]. The label instructs prescribers to inform patients of the characteristic symptom, severe persistent abdominal pain that sometimes radiates to the back and may or may not be accompanied by vomiting. If pancreatitis is suspected, Saxenda should be stopped. If it is confirmed, the drug should not be restarted.

This is not unique to Saxenda. Every FDA-approved GLP-1 receptor agonist carries the same warning. Ozempic, Wegovy, Victoza, Mounjaro, Zepbound, Trulicity, and Rybelsus all list pancreatitis in the warnings section. The FDA treats this as a class effect, meaning a property of the entire drug family rather than a quirk of one molecule ^[4].

The actual rate in trials and real-world data

In the SCALE Obesity and Prediabetes trial, the pivotal phase 3 study that supported Saxenda's FDA approval, acute pancreatitis was reported in 0.2 percent of liraglutide-treated patients versus less than 0.1 percent of placebo patients over 56 weeks ^[3]. That is roughly 1 case per 500 patients on the drug. The SCALE Diabetes trial showed similar numbers. Across the full liraglutide development program at the 3.0 mg weight-management dose, pancreatitis events occurred at about 0.2 to 0.3 percent per year of exposure.

A 2017 meta-analysis pooling 25 randomized trials of GLP-1 receptor agonists found no statistically significant increase in pancreatitis risk versus comparators in type 2 diabetes populations ^[5]. The risk signal in postmarketing reports has not been cleanly replicated in randomized data, which is one reason the FDA's 2013 investigation into incretin-mimetic pancreatitis risk concluded with a label-language clarification rather than a market withdrawal ^[4].

The catch with these numbers: people with obesity and people with type 2 diabetes already have a higher baseline rate of pancreatitis than the general population. Gallstones are more common with obesity. Hypertriglyceridemia is more common. Heavy alcohol use overlaps with weight problems in some patients. So when you see a 0.2 to 0.3 percent rate on liraglutide, that is not zero attributable risk, but it is also not a fivefold increase over what would happen anyway in this population.

Source	Pancreatitis rate	Comparator
SCALE Obesity trial (liraglutide 3.0 mg)	0.2 percent over 56 weeks	<0.1 percent on placebo
Pooled GLP-1 RCT meta-analysis (2017)	No significant increase	vs comparators
General obese/T2D population baseline	Roughly 0.2 to 0.5 per 1000 person-years	n/a
FDA postmarketing reports	"Fatal and non-fatal" cases reported	rare

Symptoms that mean stop the drug today

Acute pancreatitis has a recognizable presentation. Knowing the pattern can save you a hospital stay or a worse outcome.

The hallmark is severe, persistent pain in the upper middle abdomen that often radiates straight through to the back between the shoulder blades. It is not a stomach ache that comes and goes. It is a steady, deep, sometimes excruciating pain that builds over hours and does not improve with position changes. Lying flat often makes it worse; leaning forward sometimes brings partial relief.

The pain is usually paired with one or more of:

Nausea, often severe, with persistent vomiting
Fever, sometimes mild, sometimes high
Abdominal tenderness when you press on the upper belly
Rapid pulse and a general feeling of being very unwell
In severe cases, lightheadedness or signs of dehydration

What it is not: the normal early-treatment nausea that most Saxenda users experience during titration. That nausea is mild to moderate, comes after meals, improves over weeks, and is not paired with severe localized pain or back pain. If you are unsure whether what you are feeling is "Saxenda nausea" or something worse, the deciding feature is the pain. Routine GI side effects of Saxenda do not produce a steady, severe, back-radiating belly pain. Pancreatitis does ^[2].

Jaundice (yellowing of the eyes or skin), clay-colored stools, or dark urine on top of abdominal pain raise the concern further; those suggest the bile duct is involved, often from a gallstone, which is itself a common pancreatitis trigger.

Risk factors that raise the stakes

Some patients carry baseline features that make pancreatitis materially more likely. The Saxenda label and standard endocrinology guidance flag these:

Prior pancreatitis. A previous episode of acute or chronic pancreatitis is the strongest single predictor of another one. The FDA label does not formally contraindicate Saxenda in this group, but most prescribers avoid it ^[1].
Gallstones. Gallstones are the leading cause of acute pancreatitis worldwide. Rapid weight loss, which Saxenda produces, increases the rate of new gallstone formation. The SCALE Obesity trial showed a roughly 2.5-fold increase in cholelithiasis events on liraglutide versus placebo ^[3]. New stones can migrate into the bile duct and trigger pancreatitis.
Severe hypertriglyceridemia. Triglycerides above about 1000 mg/dL (11.3 mmol/L) are an independent cause of pancreatitis. People with familial or poorly controlled hypertriglyceridemia should have lipids checked and treated before starting Saxenda.
Heavy alcohol use. Chronic alcohol consumption is the second leading cause of acute pancreatitis. The combination of Saxenda and heavy drinking is the worst case in this list.
Personal history of pancreatic surgery, pancreatic cysts, or biliary disease. Discuss these with your prescriber before starting.

Age, sex, and ethnicity move the needle less than the items above. The eHealthMe analysis of FDA postmarketing reports notes a skew toward women aged 50 to 59, but that mostly reflects who takes Saxenda, not a true demographic risk factor.

When to stop, when to call, when to go to the ER

The decision tree is short.

Diagnosis at the hospital usually means a blood lipase test (more specific than amylase) and an abdominal ultrasound or CT scan. A lipase three times the upper limit of normal in the right clinical context confirms the diagnosis. If lipase is normal and imaging is unremarkable, the pain is something else, and Saxenda may be restartable after a conversation with your prescriber.

If pancreatitis is confirmed, the FDA label is clear: do not restart Saxenda ^[1]. Switching to a different GLP-1 receptor agonist is also generally avoided because the class warning applies to all of them. Most prescribers move to a non-GLP-1 weight-loss strategy at that point, whether that is bupropion-naltrexone, orlistat, or referral for bariatric surgery evaluation.

Why every newer GLP-1 carries the same warning

The class effect is the big-picture point. Liraglutide is one of the older molecules in the GLP-1 family. Newer drugs (semaglutide as Ozempic and Wegovy, dulaglutide as Trulicity, tirzepatide as Mounjaro and Zepbound, retatrutide in trials) all activate the GLP-1 receptor in similar ways. They all carry the same labeled pancreatitis warning. They all show pancreatitis events in trials at roughly the same low single-digit per-thousand rate.

Tirzepatide adds GIP receptor agonism on top of GLP-1. Retatrutide adds glucagon receptor agonism too. Neither change has eliminated the pancreatitis signal in their trial data. So if you are weighing alternatives because of a personal pancreatitis history, the answer is not "switch to a newer GLP-1." It is "consider a different mechanism of action altogether."

Gallstones and the indirect pancreatitis pathway

One of the more underappreciated connections: Saxenda increases gallstone formation, and gallstones cause pancreatitis. The SCALE trial showed cholelithiasis (gallstones) in 2.5 percent of Saxenda patients versus 1.0 percent on placebo, and cholecystitis (gallbladder inflammation) at higher rates too ^[3]. The mechanism is rapid weight loss plus reduced gallbladder motility, both of which favor stone formation. A stone that lodges in the bile duct backs pressure up into the pancreatic duct and triggers acute pancreatitis.

This means some "Saxenda pancreatitis" cases are technically gallstone pancreatitis with Saxenda as the upstream cause. Either way, the clinical action is the same: stop the drug, treat the acute illness, and do not restart.

Common questions about Saxenda and pancreatitis

How rare is pancreatitis on Saxenda?: About 0.2 to 0.3 percent of liraglutide users in trials versus under 0.1 percent on placebo. Roughly 1 case per 300 to 500 patient-years of treatment.
What does Saxenda pancreatitis pain feel like?: Severe, steady, deep pain in the upper middle abdomen that often radiates to the back. It is paired with persistent vomiting and sometimes fever. It is not the same as normal early-treatment nausea.
Should I stop Saxenda if my stomach hurts?: Mild GI symptoms during titration are normal. Stop and seek care for severe persistent abdominal pain, pain radiating to the back, or pain with vomiting and fever.
Can I restart Saxenda after a pancreatitis episode?: No. The FDA label says Saxenda should not be restarted if pancreatitis is confirmed. Most prescribers also avoid switching to other GLP-1 agonists since the class carries the same warning.
Does Saxenda cause gallstones?: Yes, at a higher rate than placebo. The SCALE Obesity trial showed roughly 2.5 percent on Saxenda versus 1.0 percent on placebo. Rapid weight loss is the main driver.
Does Saxenda cause hypoglycemia?: Not by itself in non-diabetic patients. The risk rises when combined with insulin or a sulfonylurea in patients with type 2 diabetes, in which case dose adjustments of those drugs are usually needed.
Is the thyroid cancer warning on Saxenda related to pancreatitis?: No. The medullary thyroid carcinoma warning comes from rodent studies and is a separate concern. It contraindicates Saxenda in people with personal or family history of MTC or MEN 2 syndrome.
Can Saxenda cause IBS, colitis, or other gut conditions?: Saxenda commonly causes nausea, diarrhea, or constipation during titration. It is not a recognized cause of inflammatory bowel disease or true IBS. New persistent gut symptoms after treatment should be evaluated on their own merits.
Does Saxenda cause hair loss, hot flashes, or acne?: Hair loss is uncommonly reported with rapid weight loss generally rather than as a direct drug effect. Hot flashes, acne, and erectile dysfunction are not established Saxenda side effects in the FDA label.
Are blood clots, seizures, or hives Saxenda side effects?: Blood clots and seizures are not labeled adverse effects. Hives and itchy skin appear in rare-frequency lists and can indicate an allergic reaction. Severe allergic symptoms require stopping the drug immediately.
Can Saxenda cause UTIs or yeast infections?: Saxenda is not associated with increased UTI or yeast infection rates. That signal exists for SGLT2 inhibitors, a different drug class for diabetes.
Does Saxenda cause cancer?: The only labeled cancer concern is medullary thyroid carcinoma, based on rodent data. Liraglutide is contraindicated in patients with personal or family history of MTC or MEN 2. There is no established link to other cancers in humans.

The bottom line

Saxenda can cause acute pancreatitis. The rate is low, in the range of 0.2 to 0.3 percent in trials, but the consequences are serious enough that the FDA labels it as a warning and instructs prescribers to stop the drug if pancreatitis is suspected and never restart it if confirmed. The symptoms that should trigger stopping are severe persistent upper-abdominal pain, especially radiating to the back, with vomiting or fever. Risk is meaningfully higher for patients with prior pancreatitis, gallstones, severe hypertriglyceridemia, or heavy alcohol use. This is a class effect across all GLP-1 receptor agonists, not a Saxenda-specific failure, and switching molecules does not solve it. Knowing the pattern is the safest tool you have.